Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
about
Fruit juice inhibition of uptake transport: a new type of food-drug interactionTime effects of food intake on the pharmacokinetics and pharmacodynamics of quazepamPotential factors involved in the causation of rhabdomyolysis following status asthmaticusClinically and pharmacologically relevant interactions of antidiabetic drugsPossible drug-drug interaction in dogs and cats resulted from alteration in drug metabolism: A mini reviewInteractions between CYP3A4 and Dietary PolyphenolsStereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juiceCarbamazepine is not a substrate for P-glycoproteinDrug- and non-drug-associated QT interval prolongation.Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical dataInhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions.Combination chemical geneticsStatin-induced rhabdomyolysis: a comprehensive review of case reports.Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions.Effects of hepatic drug-metabolizing enzyme induction on clinical pathology parameters in animals and man.Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice.Potential of an in vitro toolbox combined with exposure data as a first step for the risk assessment of dietary chemical contaminants.Safety of midazolam for sedation of HIV-positive patients undergoing colonoscopy.Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.Possible interaction of zopiclone and nefazodone.Quantification of fexofenadine in biological matrices: a review of bioanalytical methods.A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity.Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose.Review article: over-the-counter drugs and the gastrointestinal tract.Role of transport proteins in drug absorption, distribution and excretion.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.Fluconazole-induced torsade de pointes.Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.Antidepressant-induced hepatotoxicity.Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjectsEffects of grapefruit, grapefruit juice and water preloads on energy balance, weight loss, body composition, and cardiometabolic risk in free-living obese adults.The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockersStatins: balancing benefits, efficacy and safety.QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.No correlation of hsa-miR-148a with expression of PXR or CYP3A4 in human livers from Chinese Han population.
P2860
Q24630998-A750D508-23FE-4495-8AE9-21FA3744B799Q24679467-42FF1AEE-E1E6-4A87-BBF9-69B2064D21E6Q26739380-24EBF987-B82E-4F14-B13D-F6EA510AE805Q26752468-B7CE31CD-7F1F-43A2-AA0F-78C9A2DADF0CQ26800015-F2C02BF7-01C2-45BA-BD9C-3942F7D72226Q26800893-B2BD8D9C-EAFB-48B4-8797-51C81B3B3863Q28362551-557C377C-16B6-4615-A34B-CF75CE936164Q28363548-73392E42-B9A5-4222-B091-724DB6401D42Q30474909-374BFD82-4CDA-42B6-9AAD-A7A0F2C4ADC3Q30856965-7DA79D6F-3E71-44C1-B23D-C8512A558475Q32064655-471DE1A5-7735-4781-AC78-635C17371978Q33163019-3224339B-3FE5-49FC-8FC5-12C7787EBB54Q33378070-CF8EC448-EE1F-4BD5-831C-94685EBEE312Q33551640-D4DA393D-6F04-484C-B793-52E5B91B7F05Q33596382-D3DD3C82-92D2-429E-8751-5516AE44666DQ33618803-344B8494-4AC5-4B38-A5D8-56107D1CED00Q33761780-315E8014-DE6B-4D4E-91BF-32D1FFD7BC7FQ33962386-E30AAD12-C6F8-46EE-8ECD-710AB212CEA6Q33998081-8096B523-44F6-4C2A-8D2A-1FC4779EEEA0Q34085125-747CDA0F-B24E-47AF-90EE-7D82B363D575Q34093694-997CBBC2-0099-4789-95ED-B953EE2BC860Q34103348-A28C1F53-D256-43E9-AA36-2E15CFCB0816Q34166009-D92203A9-4265-4CE7-B9FF-DF0771DBDCA3Q34239110-BD53EF51-C399-4650-AAB0-9962F5226E7CQ34362478-C02ACAB9-527C-4FBC-A51E-A619484B15E6Q34365928-1422AF31-81BB-4EF7-BF54-303DBB7EFD9DQ34378917-EE152781-BDF4-407D-8265-B5E180749664Q34437996-34C9BD02-4DE3-4691-900B-EF39D606F519Q34448305-ED134F64-7770-4DC0-B216-0DAA64BDF3AEQ34466778-6F29CBF6-AFAB-47B5-9B5D-90BA8FB6EFB5Q34514672-760F8A03-E239-4377-A2B6-85EA2AB1B3F0Q34520835-EB5AE20E-A905-4793-B82E-40D44CAC31CDQ34536009-91537362-610A-435F-9E57-2FD15650416FQ34562839-62288A69-712E-4A20-92A3-7D921BF4FB9BQ34570949-D2E90B1A-CAF6-43F3-A5E8-AD9821407543Q34576491-9DD5F962-6DB7-4E68-821C-99F01A40BDBEQ34589838-A1D81681-82C1-43F9-B446-6AE27157CE94Q34628565-C7FFD382-3AA5-4FD2-BF45-142947DFD4F5Q34634216-486505A9-546A-4DA7-BAC1-8E00C51C9655Q34634718-D38F60C8-D533-4B76-B900-5127CCC88BA3
P2860
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacokinetic-pharmacodynami ...... ytochrome P450 3A4 inhibition.
@ast
Pharmacokinetic-pharmacodynami ...... ytochrome P450 3A4 inhibition.
@en
type
label
Pharmacokinetic-pharmacodynami ...... ytochrome P450 3A4 inhibition.
@ast
Pharmacokinetic-pharmacodynami ...... ytochrome P450 3A4 inhibition.
@en
prefLabel
Pharmacokinetic-pharmacodynami ...... ytochrome P450 3A4 inhibition.
@ast
Pharmacokinetic-pharmacodynami ...... ytochrome P450 3A4 inhibition.
@en
P2093
P1476
Pharmacokinetic-pharmacodynami ...... ytochrome P450 3A4 inhibition.
@en
P2093
P356
10.2165/00003088-200038010-00003
P577
2000-01-01T00:00:00Z
P6179
1025876701